EGF and breast cancer: Breast cancer MDA-MB-231 and MDA-MB-468 lines were treated with H182 for 2 h at concentrations of 0–3 μM that inhibit constitutive and ligand-induced Stat3 activation, stimulated or not with EGF for 12 min, and whole-cell lysates were prepared.